Diabetes Mellitus (Type 2)ACTIVet-2NCT05169359
Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial
A study testing Speak Up! Video in people with Diabetes Mellitus (Type 2), run by VA Office of Research and Development at 3 sites in United States.
Trial summary
Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus (Type 2)
- What is being tested?
- Speak Up! Video
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 512 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Oct 2022to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Dx of T2D
- Hemoglobin A1c ("A1c") 7 or greater
- Adults, age 18 or older
- Visit at a participating site
- Receives care from primary care provider more than once a year at VA
Who cannot join
- Lives in skilled nursing facility
- Dementia (abnormal SBT)63
- Creatinine >3 (or eGFR<20), recent MI or admission for HF
- Terminal medical condition
- Drug- (e.g., steroid) induced diabetes.
- Blind or deaf (e.g., unable to view/hear video
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Jesse Brown VA Medical Center, Chicago, IL
Chicago, Illinois, 60612
Adam Benjamin Jr VA Outpatient Clinic, Crown Point, IN
Crown Point, Indiana, 46307
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois, 60141-3030
About this study
Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Patients who use active participatory communication behaviors with their providers have better adherence to treatment and better biomedical outcomes, yet many patients are not prepared to engage in active communication with their providers. Existing coaching interventions have not been adopted in practice because of the cost of trained personnel. The investigators have shown the efficacy of a low-cost video that did not require trained personnel. This proposal proposes to test implementation strategies to deliver that video in VA primary care clinics and to test the effectiveness of the video to improve outcomes in a Hybrid Type 2 effectiveness-implementation trial using a cluster randomized stepped wedge design at eight sites. This proposal will test feasibility of implementing the video and if successful will generate the evidence to justify widespread dissemination of the video.
Read the detailed description
Background: Type 2 diabetes mellitus (T2D) affects almost one in five VA patients overall and almost one in four VA patients who are racial and ethnic minorities. Adherence to medication regimens and lifestyle factors (such as diet and exercise) is important to improve outcomes in T2D. Adherence to these factors and subsequent achievement of outcomes is related, at least in part, to effective communication in medical encounters. Empowering and activating patients to use more effective communication behaviors with their providers leads to better adherence to treatment and better biomedical outcomes. However, interventions to improve communication have not been adopted in practice largely due to the cost of trained personnel to deliver the training. Thus, there is a gap in effective interventions that can improve communication related outcomes. In a recent VA HSR\&D funded trial the investigators showed efficacy of the Speak Up! video. Veterans watching the video had significantly higher self-efficacy to communicate and lower hemoglobin A1c at follow-up.
Significance: Type 2 diabetes (T2D) is common, expensive, and chronic. Estimates put the prevalence of T2D at almost 20 percent. The proposed study is highly significant because the condition under study, T2D, is highly prevalent and has negative impacts for Veterans with the symptoms and sequelae of T2D. The objective to activate patients' communication to achieve goals of care and to improve outcomes of T2D is responsive to VA priorities to improve customer service, primary care practice, and care of complex chronic diseases.
Innovation: The proposal to engage patients in communication in medical visits is innovative because addressing patients' communication as contrasted with providers' communication is unique in the VA. It is also innovative because activating patients facilitates patient-centered care and shared decision making which are key goals in the VA/DOD guideline for the management of T2D and contributes to VA's commitment to the Whole Health model. Also, the intervention could be a paradigm for encouraging patients with other conditions to use active participatory communication. Specifically, the design and communication content of Speak Up! Could serve as a model for the development of activation interventions for Veterans with other conditions.
Specific Aims: The proposed Hybrid Type 2 study has two specific aims:
Aim 1. Implementation aim - In partnership with key clinical staff develop a strategy to deliver the Speak Up! video in VA outpatient primary care clinics using a facilitated Plan Do Study Act (PDSA) process.
Aim 2. Effectiveness aim - Examine the effectiveness of the Speak Up! video using the RE-AIM framework to evaluate Reach into the patient population, Effectiveness to improve outcomes (Hemoglobin A1c, communication self-efficacy, diabetes distress), Adoption by providers and clinics, Implementation (completion, fidelity, and intensity), and Maintenance after the end of external facilitation.
Hypothesis 1. Patients will have improvements in outcomes (A1c, diabetes distress, communication self-efficacy) from before to after watching the video.
Exploratory Hypothesis 2. Patients that are at higher risk of having challenges communicating with physicians (patients with low health literacy, African-American patients, patients with depression) will also have improvements in outcomes.
Methodology: The proposed study is a Hybrid Type 2 effectiveness - implementation trial of the intervention using a cluster-randomized stepped-wedge design in eight clinics. The investigators will test the implementation strategies using a formative evaluation guided by the Promoting Action on Research Implementation in Health Services (PARIHS) framework, and the investigators will use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework: to examine effectiveness of the Speak Up! Video; to supplement the formative evaluation from PARIHS; and to conduct a summative evaluation to evaluate success of the implementation strategies.
Implementation/Next Steps: This proposal will test the feasibility of implementing the Speak Up! video in primary care and if successful will generate the evidence to justify widespread dissemination of the video.
- Conditions
- Diabetes Mellitus (Type 2)
- Being tested
- Speak Up! Video
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Speak Up! VideoBehavioural
Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Other | The study is a type 2 hybrid Effectiveness Implementation trial. The study uses a stepped wedge design. Patients are in a usual care phase until their clinic begins active implementation. Once active implementation begins, patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or other modality such as a portable DVD player, computer, or TV as appropriate to the site based on PDSA activities during implementation planning). Nurses may also send a video link to the patient via secured messaging as a method of watching the video before the primary care visit. Receives: Behavioral: Speak Up! Video |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline HgbA1c at 3 months post-visit
HgbA1c is regarded as the standard laboratory measurement (blood test) for assessing the control of diabetes over approximately three months preceding the test. HgbA1c is usually checked several times a year in patients with poorly controlled diabetes.
Measured: Collected at baseline and 3 months post-visit
Change from pre-visit communication self-efficacy score at 1 week post visit
Communication Self-Efficacy (pre and post visit) is the degree to which a patient feels able to interact with his/her provider in order to provide information about problems, obtain desired information about diagnosis, treatment and prognosis, and participate in formulating a plan. The Perceived Efficacy in Physician-Patient Interactions scale (PEPPI) is a valid and reliable measure of patients' perceived self-efficacy in interacting with physicians (alpha 0.83). The short form of the PEPPI (PEPPI-5) has 5-items. Score on the PEPPI-5 ranges from 5-25. Higher scores reflect a better perceived self-efficacy in interacting with physicians.
Measured: Collected at pre-visit and 1 week post-visit
Change from pre-visit diabetes distress score at 1 week post visit
Diabetes Distress is a 17-item scale that measures the emotional burden of diabetes on four subscales: emotional burden, physician-related distress, regimen-related distress, and diabetes-related interpersonal distress subscale. The Diabetes Distress scale is internally consistent and is well correlated with measures of depression, meal planning, exercise, and cholesterol levels. The scale ranges from 17 to 102. Higher scores indicate higher distress.
Measured: Collected at pre-visit and 1 week post-visit
Secondary outcomes (11)
Change from baseline trust in provider score at 1 week post visit
Trust in Provider is measured pre- and post visit using a 5-item measure. The scale is scored on a 7-point Likert scale using the anchors "strongly disagree" and "strongly agree". The scale ranges from 5 to 35. Higher scores reflect higher trust in provider.
Measured: Collected at baseline and 1 week post-visit
Change from pre-visit patient engagement score at 1 week post visit
Patient Engagement is assessed with the Altarum Consumer Engagement (ACE) measure. We use 8-items from two subscales (commitment and navigation). The scale ranges from 8 to 40. Higher scores are associated with higher patient's engagement in their healthcare.
Measured: Collected at pre-visit and 1 week post-visit
Change from pre-visit medication adherence at 1 week post visit
This measure of medication adherence is the 9-item Brief Medication Questionnaire (BMQ), a highly sensitive scale for identifying non-adherence. The scale ranges from 9 to 45. Higher scores indicate more non-adherence.
Measured: Collected at pre-visit and 1 week post-visit
Change from pre-visit self-care score at 1 week post visit
Self-Care will be measured with the Summary of Diabetes Self Care Activities (SDSCA) a well validated measure that assesses self-care activities (e.g., diet, physical activity, and smoking) The scale ranges from 12 to 96. Higher scores indicate better diabetes self-care.
Measured: Collected at pre-visit and 1 week post-visit
Shared decision making
Shared Decision Making (SDM) will be measured with the CollaboRATE. The scale ranges from 0 to 27. Higher scores indicate higher shared decision making. This measure assesses discussion of options, pros, cons and preferences of a health decision. Higher scores indicate greater shared decision making.
Measured: Collected 1 week post visit
Communication Ratings
The questionnaire assesses patients' ratings of their own participatory communication behavior. It is a 5-item scale. The scale is scored from 1 (completely disagree) to 7 (completely agree). The higher scores indicate a better quality of communication. The scale ranges from 5 to 35.
Measured: Collected 1 week post visit
Patient Centered Care
Patient-Centered Care is measured with the Consultation Care Measure (CCM). The CCM measures patients' ratings of their provider on five subscales. The scale ranges from 21 to 105. Higher scores are associated with higher patient ratings of their provider.
Measured: Collected 1 week post visit
Change from pre-visit medication adherence at 3 months post visit
Medication adherence will also be assessed with a medication possession ratio (MPR) for diabetes medications. MPR will be based on VA pharmacy data. MPR is a ratio of the number of days the patient has drug in their possession divided by the number of days in the follow-up period (MPR = days with drug / total days). The investigators will use a mean MPR for patients on multiple oral hypoglycemic medications.
Measured: Collected at pre-visit and 3 months post visit
Change from baseline functional status score at 1 week post visit
Functional Status will be assessed with the Veterans RAND-12 (VR-12), a patient-reported global-health measure of physical and mental health status and that has a non-proprietary scoring algorithm. The scale is normalized to a range from 0-100; higher scores indicate better functional status.
Measured: Collected at baseline and 1 week post visit
Change from pre-visit self-management score at 1 week post visit
Diabetes self-management will be measured using the Diabetes Management Self Efficacy (DMSE) scale (alpha 0.91). This scale has 20 items. The scale ranges from 20 to 80. Higher scores indicate better diabetes self-management.
Measured: Collected at pre-visit and 1 week post visit
Promis
Patient engagement will be assessed with the PROMIS Healthcare engagement measure including 8 items. Scores range from 8-40. Higher scores indicate higher healthcare engagement for patients.
Measured: Change from baseline promis score at 1 week post visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2021
- Study start1 Oct 2022
- Primary completion30 Jun 2025
- Study completion31 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus (Type 2)Studies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Sequential
- Model description
- Stepped wedge design
- Masking
- None (open label)
- Enrolment
- 512 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Howard S. Gordon, MD BS, Principal investigator, Jesse Brown VA Medical Center, Chicago, IL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05169359
- Sponsor's protocol ID
- IIR 19-442
- Acronym
- ACTIVet-2
- Status last verified
- Jul 2025
- First submitted
- 2 Dec 2021
- Last updated
- 20 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Final datasets underlying all publications resulting from the proposed research will not be shared outside VA, except as required under the Freedom of Information Act (FOIA), for the for the following reasons: Data will be collected and accessed with a waiver of HIPAA authorization and as such disclosure outside the VA is restricted. For appropriate requests we will seek IRB and privacy officer approval for release of de-identified anonymized data.
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05169359
- Acronym / sponsor ID
- ACTIVet-2 / IIR 19-442
- Conditions
- Diabetes Mellitus (Type 2)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 512 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 1 Oct 2022 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 31 Mar 2026 (estimated)
- First posted
- 23 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Patients who use active participatory communication behaviors with their providers have better adherence to treatment and better biomedical outcomes, yet many patients are not prepared to engage in active communication with their providers. Existing coaching interventions have not been adopted in practice because of the cost of trained personnel. The investigators have shown the efficacy of a low-cost video that did not require trained personnel. This proposal proposes to test implementation strategies to deliver that video in VA primary care clinics and to test the effectiveness of the video to improve outcomes in a Hybrid Type 2 effectiveness-implementation trial using a cluster randomized stepped wedge design at eight sites. This proposal will test feasibility of implementing the video and if successful will generate the evidence to justify widespread dissemination of the video.
Detailed description
Background: Type 2 diabetes mellitus (T2D) affects almost one in five VA patients overall and almost one in four VA patients who are racial and ethnic minorities. Adherence to medication regimens and lifestyle factors (such as diet and exercise) is important to improve outcomes in T2D. Adherence to these factors and subsequent achievement of outcomes is related, at least in part, to effective communication in medical encounters. Empowering and activating patients to use more effective communication behaviors with their providers leads to better adherence to treatment and better biomedical outcomes. However, interventions to improve communication have not been adopted in practice largely due to the cost of trained personnel to deliver the training. Thus, there is a gap in effective interventions that can improve communication related outcomes. In a recent VA HSR\&D funded trial the investigators showed efficacy of the Speak Up! video. Veterans watching the video had significantly higher self-efficacy to communicate and lower hemoglobin A1c at follow-up.
Significance: Type 2 diabetes (T2D) is common, expensive, and chronic. Estimates put the prevalence of T2D at almost 20 percent. The proposed study is highly significant because the condition under study, T2D, is highly prevalent and has negative impacts for Veterans with the symptoms and sequelae of T2D. The objective to activate patients' communication to achieve goals of care and to improve outcomes of T2D is responsive to VA priorities to improve customer service, primary care practice, and care of complex chronic diseases.
Innovation: The proposal to engage patients in communication in medical visits is innovative because addressing patients' communication as contrasted with providers' communication is unique in the VA. It is also innovative because activating patients facilitates patient-centered care and shared decision making which are key goals in the VA/DOD guideline for the management of T2D and contributes to VA's commitment to the Whole Health model. Also, the intervention could be a paradigm for encouraging patients with other conditions to use active participatory communication. Specifically, the design and communication content of Speak Up! Could serve as a model for the development of activation interventions for Veterans with other conditions.
Specific Aims: The proposed Hybrid Type 2 study has two specific aims:
Aim 1. Implementation aim - In partnership with key clinical staff develop a strategy to deliver the Speak Up! video in VA outpatient primary care clinics using a facilitated Plan Do Study Act (PDSA) process.
Aim 2. Effectiveness aim - Examine the effectiveness of the Speak Up! video using the RE-AIM framework to evaluate Reach into the patient population, Effectiveness to improve outcomes (Hemoglobin A1c, communication self-efficacy, diabetes distress), Adoption by providers and clinics, Implementation (completion, fidelity, and intensity), and Maintenance after the end of external facilitation.
Hypothesis 1. Patients will have improvements in outcomes (A1c, diabetes distress, communication self-efficacy) from before to after watching the video.
Exploratory Hypothesis 2. Patients that are at higher risk of having challenges communicating with physicians (patients with low health literacy, African-American patients, patients with depression) will also have improvements in outcomes.
Methodology: The proposed study is a Hybrid Type 2 effectiveness - implementation trial of the intervention using a cluster-randomized stepped-wedge design in eight clinics. The investigators will test the implementation strategies using a formative evaluation guided by the Promoting Action on Research Implementation in Health Services (PARIHS) framework, and the investigators will use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework: to examine effectiveness of the Speak Up! Video; to supplement the formative evaluation from PARIHS; and to conduct a summative evaluation to evaluate success of the implementation strategies.
Implementation/Next Steps: This proposal will test the feasibility of implementing the Speak Up! video in primary care and if successful will generate the evidence to justify widespread dissemination of the video.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Stepped wedge design
| Arm | Type | Receives |
|---|---|---|
| Intervention | Other | Behavioral: Speak Up! VideoThe study is a type 2 hybrid Effectiveness Implementation trial. The study uses a stepped wedge design. Patients are in a usual care phase until their clinic begins active implementation. Once active implementation begins, patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or other modality such as a portable DVD player, computer, or TV as appropriate to the site based on PDSA activities during implementation planning). Nurses may also send a video link to the patient via secured messaging as a method of watching the video before the primary care visit. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Dx of T2D
- Hemoglobin A1c ("A1c") 7 or greater
- Adults, age 18 or older
- Visit at a participating site
- Receives care from primary care provider more than once a year at VA
Key exclusion criteria (6 listed)
- Lives in skilled nursing facility
- Dementia (abnormal SBT)63
- Creatinine >3 (or eGFR<20), recent MI or admission for HF
- Terminal medical condition
- Drug- (e.g., steroid) induced diabetes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Speak Up! VideoOnce a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones. | Behavioural | Intervention |
Primary outcome
Change from baseline HgbA1c at 3 months post-visit
Time frame: Collected at baseline and 3 months post-visit
HgbA1c is regarded as the standard laboratory measurement (blood test) for assessing the control of diabetes over approximately three months preceding the test. HgbA1c is usually checked several times a year in patients with poorly controlled diabetes.
Change from pre-visit communication self-efficacy score at 1 week post visit
Time frame: Collected at pre-visit and 1 week post-visit
Communication Self-Efficacy (pre and post visit) is the degree to which a patient feels able to interact with his/her provider in order to provide information about problems, obtain desired information about diagnosis, treatment and prognosis, and participate in formulating a plan. The Perceived Efficacy in Physician-Patient Interactions scale (PEPPI) is a valid and reliable measure of patients' perceived self-efficacy in interacting with physicians (alpha 0.83). The short form of the PEPPI (PEPPI-5) has 5-items. Score on the PEPPI-5 ranges from 5-25. Higher scores reflect a better perceived self-efficacy in interacting with physicians.
Change from pre-visit diabetes distress score at 1 week post visit
Time frame: Collected at pre-visit and 1 week post-visit
Diabetes Distress is a 17-item scale that measures the emotional burden of diabetes on four subscales: emotional burden, physician-related distress, regimen-related distress, and diabetes-related interpersonal distress subscale. The Diabetes Distress scale is internally consistent and is well correlated with measures of depression, meal planning, exercise, and cholesterol levels. The scale ranges from 17 to 102. Higher scores indicate higher distress.
11 secondary outcomes
Change from baseline trust in provider score at 1 week post visit
Time frame: Collected at baseline and 1 week post-visit
Change from pre-visit patient engagement score at 1 week post visit
Time frame: Collected at pre-visit and 1 week post-visit
Change from pre-visit medication adherence at 1 week post visit
Time frame: Collected at pre-visit and 1 week post-visit
Change from pre-visit self-care score at 1 week post visit
Time frame: Collected at pre-visit and 1 week post-visit
Shared decision making
Time frame: Collected 1 week post visit
Communication Ratings
Time frame: Collected 1 week post visit
Patient Centered Care
Time frame: Collected 1 week post visit
Change from pre-visit medication adherence at 3 months post visit
Time frame: Collected at pre-visit and 3 months post visit
Change from baseline functional status score at 1 week post visit
Time frame: Collected at baseline and 1 week post visit
Change from pre-visit self-management score at 1 week post visit
Time frame: Collected at pre-visit and 1 week post visit
Promis
Time frame: Change from baseline promis score at 1 week post visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2025.
- Individual participant dataSharing planned: Yes. Final datasets underlying all publications resulting from the proposed research will not be shared outside VA, except as required under the Freedom of Information Act (FOIA), for the for the following reasons: Data will be collected and accessed with a waiver of HIPAA authorization and as such disclosure outside the VA is restricted. For appropriate requests we will seek IRB and privacy officer approval for release of de-identified anonymized data.
Related trials for Diabetes Mellitus (Type 2)
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Howard S. Gordon, MD BS principal investigator
Jesse Brown VA Medical Center, Chicago, IL
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Speak Up! Video in people with Diabetes Mellitus (Type 2), run by VA Office of Research and Development at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline HgbA1c at 3 months post-visit (time frame: Collected at baseline and 3 months post-visit). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2025.